French pharmaceutical giant Sanofi SA (SNY.US) reported its first-quarter 2026 financial results on Thursday. Driven by sustained strong demand for its core product Dupixent, the company's revenue and profit both exceeded market expectations, providing a welcome gift for incoming Chief Executive Officer Belén Garijo, who is set to officially take office at the end of the month. However, market focus has quickly shifted to how Garijo will address the strategic challenges of a weak development pipeline and the upcoming patent expiration for Dupixent.
**Strong Results Led by Blockbuster Drug** Financial reports show that for the quarter ended March 31, Sanofi achieved total sales of 10.51 billion euros (approximately $12.29 billion), surpassing the analyst consensus estimate of 10.22 billion euros. Business operating profit reached 2.97 billion euros (approximately $3.47 billion), also exceeding market expectations of 2.85 billion euros. Earnings per share, excluding certain items, were 1.88 euros (approximately $2.20), beating the analyst forecast of 1.78 euros.
The primary driver of the better-than-expected performance remained the blockbuster product Dupixent. Sales for this drug, used to treat asthma and atopic dermatitis, grew 30.8% at constant exchange rates to 4.17 billion euros for the quarter, significantly exceeding analyst expectations of 3.89 billion euros. The vaccines division recorded sales of 1.3 billion euros, slightly above the expected 1.29 billion euros, as robust demand for polio and whooping cough combination vaccines partially offset weaker sales of flu vaccines and the RSV antibody Beyfortus.
**New CEO Faces Core Test of R&D Efficiency** This strong report card comes during a critical leadership transition period for Sanofi. Former CEO Paul Hudson was ousted by the board in February after failing to advance a promising new drug pipeline in a timely manner, which contributed to pressure on the stock price. Garijo, who has 15 years of tenure at Sanofi and previously led Merck KGaA, will officially assume her role on April 29.
Investors have high hopes for Garijo but have also clearly identified her biggest challenge: improving R&D output efficiency and reducing reliance on Dupixent. Dupixent's patent is set to expire early in the next decade, and Sanofi has yet to present a clear replacement strategy capable of filling the potential revenue gap. Over the past 12 months, weighed down by a series of mixed or negative clinical trial results, Sanofi's stock price has declined by approximately 13%.
Addressing this, Sanofi's Chief Financial Officer, François Roger, acknowledged during an earnings call that the company indeed faced R&D setbacks last year but emphasized that "R&D needs to be viewed with a long-term perspective." He revealed that Garijo's arrival presents an opportunity to re-evaluate strategy, including "whether we wish to expand into other potential therapeutic areas." He added that the company possesses a diversified portfolio of assets and is not reliant on a single drug.
**Outlook and Concerns: Currency Headwinds and Vaccine Policy Shifts** Sanofi reaffirmed its full-year guidance, anticipating sales growth in the high-single-digit percentage range at constant exchange rates, with business operating profit growing slightly faster than sales.
Senior analyst John Murphy noted that Sanofi is positioned to potentially exceed this guidance, but market attention is now focused on potential strategic changes under the new CEO.
Sanofi also highlighted near-term headwinds. The company stated that currency fluctuations had a negative impact of 7.4 percentage points on sales growth. Furthermore, the outlook for the vaccines business is uncertain. Sanofi expects vaccine sales to decline slightly this year, influenced by factors including changes in vaccine policy being implemented by U.S. Health Secretary Robert F. Kennedy Jr.
In response to widespread industry concerns about whether U.S. drug pricing pressures might delay European launches, Roger stated that Sanofi plans to launch any product in Europe concurrently with its U.S. launch. However, he acknowledged that drug prices may change, with pricing levels in some countries "likely to see a slight increase."
Comments